



EVITRADE Health Systems to Bring Blockchain Security to The Hemp Industry

VANCOUVER, BC, Monday June 11, 2018 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the “Company”) announces that it has embarked on a program to utilize its contacts in the blockchain technology space to marry the security of blockchain technology with the Company’s interest in the international industrial Hemp trade.

The Company has signed a Letter of Intent with Veri-Medical Systems (“VeriMed” or the “Company”) to potentially acquire the Company which is involved in developing a blockchain based “seed-to-sale” protocol focussed on enhancing the integrity of the sale of Hemp based products such as cannabidiol (“CBD”). “We are very excited to be standing at the cross-road of being able to combine the security that block-chain technologies offer with the bright future of Hemp based protocols and products” said C.K., CEO for Evitrade Health.

With impending legalization rules for cannabis in Canada and potentially Hemp based products right behind that, the Company is preparing to lead the industry with their technology insights and access to some of possibly the best minds and scientists for the industry.

Management continues to strive to seek optimal business and commercialization strategies for the Company; This, with the continued relationship with Haywood Securities as financial advisor, has the Company planning forward for a bright future.

Contact: C.K. Cheung, CEO

EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets: <http://www.otcmarkets.com/stock/AXHLF/news>

About EVITRADE Health (CSE: EVA, OTCQB: AXHLF)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online “digital healthcare” services for resolving common health problems. The current markets are weight-management, high blood pressure, high blood glucose and heart arrhythmia.

Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcmarkets.com/stock/AXHLF/filings>. This news release does not constitute an offer to sell or



**EViTRADE
Health
Systems
Corporation**

solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.